PAX Financial Group’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $681K | Sell |
5,421
-2,517
| -32% | -$316K | 0.13% | 118 |
|
|
2025
Q1 | $878K | Buy |
7,938
+11
| +0.1% | +$1.22K | 0.16% | 113 |
|
|
2024
Q4 | $1.08M | Sell |
7,927
-281
| -3% | -$38.4K | 0.19% | 96 |
|
|
2024
Q3 | $946K | Sell |
8,208
-605
| -7% | -$69.7K | 0.17% | 107 |
|
|
2024
Q2 | $1.21M | Sell |
8,813
-1,134
| -11% | -$156K | 0.24% | 78 |
|
|
2024
Q1 | $1.37M | Sell |
9,947
-432
| -4% | -$59.6K | 0.28% | 72 |
|
|
2023
Q4 | $1.4M | Sell |
10,379
-1,202
| -10% | -$162K | 0.29% | 63 |
|
|
2023
Q3 | $1.3M | Sell |
11,581
-5,891
| -34% | -$663K | 0.3% | 62 |
|
|
2023
Q2 | $1.65M | Buy |
17,472
+1,217
| +7% | +$115K | 0.37% | 49 |
|
|
2023
Q1 | $1.65M | Buy |
+16,255
| New | +$1.65M | 0.39% | 46 |
|